Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection
Sponsor and Collaborators
Tolera Therapeutics, Inc
Leslie O’Toole, RN
269-585-2100 ext 2111
Stuart Flechner, MD
The Cleveland Clinic
Next post in Renal Transplant Clinical Trials
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
Want to read more?
Please login or register first to view this content.